The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: A meta-analysis

Pharmacogenetics

Volumn 8, Issue 6, 1998, Pages 473-479

  Christensen, Palle Mark ^a,c   Gøtzsche, Peter C ^b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b University of Copenhagen   (Denmark)

^c IMB   (Denmark)

Author keywords

CYP2D6; Meta analysis; Parkinson's disease; Sparteine debrisoquine polymorphism

Indexed keywords

DEBRISOQUINE; SPARTEINE;

ARTICLE; CASE CONTROL STUDY; DRUG METABOLISM; DRUG OXIDATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; GENETIC HETEROGENEITY; HUMANS; MIDDLE AGED; ODDS RATIO; OXIDATION-REDUCTION; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RISK FACTORS; SPARTEINE;

EID: 0032423064     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Agundez JAG, Jimenez-Jimenez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995; 57:291-298.
2. Alvan G, Bechtel P, Iselius L, Gundert Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-537.
3. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339:1017-1018.
4. Barbeau A, Roy M, Paris S, Cloutier T, Plasse L, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; 30:1213-1215.
5. Benitez J, Ladero JM, Jiménez-Jiménez FJ, Martinez C, Puerto AM, Valdivielso MJ, et al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psych 1990; 53:289-292.
6. Bordet R, Broly F, Desteé A, Libersa C. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Adv Neurol 1996; 69:97-100.
7. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36:537-547.
8. Chiba K, Imai H, Yoshino H, Kato J, Ishizaki T, Narabayashi H. Sparteine oxidation in patients with early and late-onset of Parkinson's disease. Clin Neurol 1993; 33:103-109.
9. Christensen PM, Gotzsche PC, Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 1997; 51:389-393.
10. Comella CL, Tanner CM, Goetz CG, Gans S, Rapp D, Fischer J. Debrisoquine metabolism in Parkinson's disease. Neurology 1987; 37(Suppl 1):261-262.
11. Diederich N, Hilger C, Goetz CG, Keipes M, Hentges F, Vieregge P, Metz H. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996; 40:463-465.
12. Fonne Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and nit cytochrome P450 isozymes (P450bufl, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987; 148:1144-1150.
13. Gasser T, Müller-Myhsok B, Supala A, Zimmer G, Wieditz G, Wszolek ZK, et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psych 1996; 61:518-520.
14. Gudjonsson O, Sanz E, Alvan G, Aquilonius SM, Reviriego J. Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30:301-502.
15. Heim M, Meyer UA. Genotypingof poor metabolisers of debrisoquine by allele-specific PCR amplification [see comments]. Lancet 1990; 336:529-532.
16. Kallio J, Marttila RJ, Rinne UK, Sonninen V, Syvaelahti E, Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand 1991; 83:194-197.
17. Kalow W, Tyndale RF. Debrisoquine/sparteine monooxygenase and other P-450s in the brain. In: Kalow W. editors. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. pp. 649-656.
18. Kondo I, Kanazawa, I. Association of Xba I allele (Xba I 44 kb) of the human cytochrome P-450dbl (CYP2D6) gene in Japanese patients with idiopathic Parkinsons's disease. Adv Neurol 1993; 60:338-342.
19. Kurth MC, Kurth JH. Variant cytochrome P455 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Gen 1993; 48:166-168.
20. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G. Gene-environment interaction in Parkinson's disease. The cease of CYP2D6 gene polymorphism. Adv Neurol 1996; 69:61-72.
21. Liu TY, Chi CW, Yang JC, Cheung SC, Liu HC. Debrisoquine metabolism in Chinese patients with Alzheimer's and Parkinson's diseases. Mol Chem Neuropathol 1992; 17:31-37.
22. Lucotte G, Turpin JC, Gerard N, Panserat S, Krishnamoorthy R. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson's disease patients and in families. Am J Med Gen 1996; 67:361-365.
23. Marsden CD, Parkinson's disease. Lancet 1990; 335:948-952.
24. Meillard MN, Bentue-Ferrer D, Brunet-Bourgin F, Morel G, Allain H. Etude de l'hydroxylation de la debrisoquine dans la maladie de Parkinson. Presse Med 1990; 19:947-949.
25. Ohta S, Tachikawa O, Makino Y, Tasaki Y, Hirobe M. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci 1990; 46:599-605.
26. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: a survey of three medical journals. N Engl J Med 1987; 317:426-432.
27. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet 1987; 2:386.
28. Rijk MC, Tzourio C, Breteler NM, Dartigues JF, Amaducci L, Lopez-Pousa S. et al. Prevalence of parkinsonism and Parkinson's disease in Europe: The Europarkinson Collaborative Study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62:10-15.
29. Sandy MS, Armstrong M, Tanner CM, Daly AK, Di Monte DA. Langston JW, Idle JR. CYP2D6 allelic frequencies in young onset Parkinson's disease. Neurology 1996; 47:225-230.
30. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinsons's disease. Lancet 1992; 339:1375-1377.
31. Steiger M. Lledo P, Quinn N, Marsden C, Turner P, Jenner PG. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992; 86:159-164.
32. Steventon GB, Haefield MTH, Sturman SG, Waring RH, Williams AC, Ellingham J. Degenerative neurological disease and debrisoquine-4-hydroxylation capacity. Med Sci Res 1989; 17:163-164.
33. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991; 40:63-68.
34. Zang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuropidemiology 1993; 12:195-208.
35. Zanger UM, Vilbois F, Hardwick JP, Meyer UA. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27:5447-5454.